Large B-cell Lymphoma Clinical Trial
— PORTALOfficial title:
A Phase II Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma
The PORTAL study will test a new combination of drugs (glofitamab, polatuzumab vedotin and obinutuzumab) in patients with large B-cell lymphoma (LBCL) that has come back (relapsed) or not responded to previous treatment. It will determine how safe and effective the combination of these cancer drugs is in treating LBCL before and after CAR-T cell therapy.
Status | Not yet recruiting |
Enrollment | 99 |
Est. completion date | July 31, 2028 |
Est. primary completion date | January 31, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically proven CD20+ LBCL (with CD20 positivity at any timepoint) including diffuse large B cell lymphoma, high grade B cell lymphoma with MYC, BCL2 and/or BCL6 (double/triple hit lymphoma), high grade B cell lymphoma not otherwise specified (NOS), primary mediastinal B-cell lymphoma or transformed follicular lymphoma. - Part 1: Relapsed or refractory disease and eligible for CAR T-cell therapy in the UK and in need of systemic bridging in the opinion of the local investigator. - Part 2: Failed to achieve CMR (Deauville score 1-3) on PET scan 1-month post CAR-T or progressed at any point post CAR-T (patients in part 2 may have been previously enrolled in Part 1 and responded to Pola-Glofit bridging or be de novo patients who are naïve to this combination) - At least one measurable target lesion - Patient has recent archival biopsy tissue available or is willing to undergo a new biopsy. - ECOG performance status: - Part 1: ECOG PS 0/1 - Part 2: ECOG PS 0-2 - Life expectancy of = 12 weeks - Adequate haematological status. - Adequate liver and renal function - Negative test for hepatitis B, hepatitis C, HIV and SARS-CoV-2 Exclusion Criteria: - Patients with known active infection - Current = Grade 2 peripheral neuropathy - History of confirmed progressive multifocal leukoencephalopathy - Current evidence of CNS lymphoma - Patients with another invasive malignancy in the last 2 years - Significant history of cardiovascular disease - Active autoimmune disease or immune deficiency - Severe neurological disorder - Uncontrolled tumour-related pain - Uncontrolled pleural effusion, pericardial effusion, or ascites - Treatment with other standard anti-cancer radiotherapy/chemotherapy including investigational therapy and targeted therapy within 4 weeks prior to cycle 1 day 1 - Prior solid organ transplantation - Prior allogeneic stem cell transplant - Autologous SCT within 100 days prior to cycle 1 day 1 - Any history of immune related = Grade 3 adverse events - Ongoing corticosteroid use > 25 mg/day of prednisone or equivalent within 4 weeks prior to study treatment - Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment - Administration of a live, attenuated vaccine within 4 weeks prior to cycle 1 day 1 - History of severe allergic anaphylactic reactions to chimeric or humanised monoclonal antibodies or recombinant antibody-related fusion proteins. - Known hypersensitivity to Chinese hamster ovary cell products or to any component of the obinutuzumab, polatuzumab vedotin and/or glofitamab formulation. - Known or suspected history of HLH |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University College, London | Hoffmann-La Roche |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Part 1: Overall Response Rate (ORR) to Pola-Glofit as bridging prior to CAR-T cell infusion | To determine the efficacy of Pola-Glofit as bridging treatment to CAR-T cell therapy in patients with r/r LBCL.
ORR i.e. the proportion of patients achieving response (Complete Metabolic Response or Partial Metabolic Response) after Pola-Glofit bridging but prior to CAR-T cell infusion, assessed by central review as per 2014 Lugano Classification. This will be presented as a rate with a 70% confidence interval. |
At Cycle 2 Day 14-19 (or earlier) (each cycle is 21 days) | |
Primary | Part 2: Progression Free Survival (PFS) at 6 months | To determine the efficacy of Pola-Glofit in patients with LBCL who have failed to achieve CMR, or progressed after CAR-T cell therapy.
PFS at 6 months will be analysed using Kaplan-Meier survival analysis, with the rate at 6 months (with 70% CI) presented. The median (if reached) and plot will also be given. |
From the date of registration at Part 2 until the date of first disease progression or death, whichever comes first, assessed up to 4 years | |
Secondary | Part 1: Complete Metabolic Response (CMR) rate to Pola-Glofit as bridging prior to CAR-T cell infusion | Per Lugano 2014 criteria | At Cycle 2 Day 14-19 of bridging treatment (each cycle is 21 days) | |
Secondary | Part 1: Overall Survival (OS) and Progression Free Survival (PFS) | Medians (if reached), rates at 6 months and 1 year and plots will be presented | From the date of registration at Part 1 until the date of disease progression or death (PFS), or death (OS). This will be assessed from the date of registration until up to 4 years. | |
Secondary | Part 1: Safety and toxicity of Pola-Glofit as bridging therapy | Assessed by CTCAE criteria v5 and ASTCT 2019 criteria for CRS/ICANS adverse events. Assessed in all patients given at least one dose of study treatment in part 1. | From registration and during Part 1 bridging treatment, until end of post-treatment safety reporting window (up to six months after last dose of obinutuzumab, plus a further 35 days after last dose of polatuzumab vedotin or last dose of glofitamab) | |
Secondary | Part 1: CAR-T associated toxicity post Pola-Glofit bridging following CAR-T therapy | Assessed in all patients given at least one dose of study treatment in part 1 and infused. Assessed by CTCAE criteria v5 and ASTCT 2019 criteria for CRS/ICANS adverse events. | Between Day 0 and Day 28 following CAR-T therapy | |
Secondary | Part 1: Response rate post CAR-T for all infused patients | Per Lugano 2014 criteria. Response rates at 1, 3 and 6 months post CAR-T therapy. | From CAR-T infusion until 6 months post CAR-T therapy | |
Secondary | Part 1: Duration of Response (DoR) and Duration of Complete Response (DoCR) for Pola-Glofit and CAR-T | Response defined as PR (partial response) or better. | From the date of first response until disease progression. This will be assessed from the date of registration until up to 4 years. | |
Secondary | Part 1: Non-Relapse Mortality (NRM) | NRM rates at 6 months and 1 year | From the date of registration until the date of NRM. This will be assessed from the date of registration until up to 4 years. | |
Secondary | Part 2: Complete Metabolic Response (CMR) rate to Pola-Glofit/Glofitamab at any point | Per Lugano 2014 criteria | From the date of registration until up to 4 years | |
Secondary | Part 2: Response rate for patients who received Pola-Glofit bridging versus those who have not | Per Lugano 2014 criteria. Response rates following 2 and 5 cycles of Part 2 treatment. | From the date of registration until Cycle 5 (approximately 12 weeks. Each cycle is 21 days). | |
Secondary | Part 2: Safety and toxicity of Pola-Glofit post CAR-T therapy | Assessed by CTCAE criteria v5 and ASTCT 2019 criteria for CRS/ICANS adverse events. Assessed in all patients given at least one dose of study treatment in part 2. | Throughout Part 2 treatment until end of post-treatment safety reporting window (up to six months after last dose of obinutuzumab, plus a further 35 days after last dose of polatuzumab vedotin or last dose of glofitamab) | |
Secondary | Part 2: Overall Survival (OS) | Median (if reached), rates at 6 months and 1 year (with 95% CIs) and plots will be presented. | From the date of registration for Part 2 until the date of death, assessed up to 4 years. | |
Secondary | Part 2: Duration of Response (DoR) | Response defined as PMR (partial metabolic response) or better. | From the date of first response until disease progression, assessed up to 4 years. | |
Secondary | Part 2: Duration of Complete Response (DoCR) | From the date of first complete metabolic response (CMR) until disease progression, assessed up to 4 years. | ||
Secondary | Part 2: Non-Relapse Mortality (NRM) | NRM rates will be presented at 6 months and 1 year. | NRM will be measured from the date of registration until the date of NRM. This will be assessed from the date of registration until up to 4 years. NRM rates will be presented at 6 months and 1 year. | |
Secondary | Part 2: Progression Free Survival (PFS) (at 12 months) | Median (if reached), rate at 12 months (with 95% CI) and plot will be presented | PSF will be measured from the date of registration at Part 2 until the date of disease progression. This will be assessed from the date of registration until up to 4 years. The median rate at 12 months will be presented. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05929716 -
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT05464719 -
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
|
Phase 2 | |
Recruiting |
NCT06047080 -
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
|
Phase 3 | |
Active, not recruiting |
NCT04566978 -
89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)
|
Early Phase 1 | |
Recruiting |
NCT06104592 -
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
|
Phase 2 | |
Recruiting |
NCT04889716 -
CAR-T Followed by Bispecific Antibodies
|
Phase 2 | |
Recruiting |
NCT04250324 -
Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT05326243 -
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05794958 -
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
|
Phase 1 | |
Recruiting |
NCT06285422 -
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
|
Phase 1 | |
Recruiting |
NCT05404048 -
PD-L1 PET-imaging During CAR T-cell Therapy
|
Phase 2 | |
Recruiting |
NCT06375733 -
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
|
Phase 1/Phase 2 | |
Recruiting |
NCT05887167 -
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
|
Phase 1 | |
Recruiting |
NCT05648019 -
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
|
Phase 2 | |
Recruiting |
NCT05643742 -
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05820841 -
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Recruiting |
NCT05472610 -
Study of Efficacy of BZ019 in Large B-cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT03960840 -
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL
|
Phase 1/Phase 2 | |
Recruiting |
NCT06356129 -
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
|
Phase 3 | |
Recruiting |
NCT05665062 -
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
|
Phase 1 |